---
title: "浙江花园生物医药股份有限公司 (300401.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300401.SZ.md"
symbol: "300401.SZ"
name: "浙江花园生物医药股份有限公司"
industry: "制药"
---

# 浙江花园生物医药股份有限公司 (300401.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.hybiotech.com](https://www.hybiotech.com) |

## Company Profile

公司成立于 2000 年 12 月，于 2014 年 10 月 9 日在深圳证券交易所创业板挂牌上市。经过二十多年的发展，已经完成了维生素 D3 全产业链的布局。公司四大类产品精制羊毛脂、羊毛脂胆固醇、维生素 D3、25-羟基维生素 D3 的产能规模都处于全球领先位置，拥有市场主导权。公司生产经营主要涉及维生素和医药制造两大行业。公司主要产品有羊毛脂胆固醇、维生素 D3、25-羟基维生素 D3、维生素 A 等;缬沙坦氨氯地平片 (I)、多索茶碱注射液、左氧氟沙星片、硫辛酸注射液、草酸艾司西酞普兰片、奥美拉唑碳酸氢钠胶囊、多巴丝肼片、氨氯地平阿托伐他汀钙片、罗红霉素片、阿仑膦酸钠片等。企业荣誉：...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 107 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.43% |  |
| Net Profit YoY | 5.94% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.93 |  |
| Dividend Ratio | 0.67% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9.25B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.24B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.20% | B |
| Profit Margin | 24.31% | A |
| Gross Margin | 54.57% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.43% | B |
| Net Profit YoY | 5.94% | C |
| Total Assets YoY | 6.92% | B |
| Net Assets YoY | 8.82% | B |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 411.33% | C |
| OCF YoY | 9.43% | B |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.22 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 42.19% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 浙江花园生物医药股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.20%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "24.31%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "54.57%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.43%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "5.94%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.92%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.82%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "411.33%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "9.43%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "42.19%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 30.65 | 75/222 | 28.23 | 26.11 | 24.34 |
| PB | 2.93 | 131/222 | 2.85 | 2.63 | 2.46 |
| PS (TTM) | 7.45 | 156/222 | 7.06 | 6.61 | 6.09 |
| Dividend Yield | 0.67% | 118/222 | 0.81% | 0.75% | 0.63% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-26T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.02 |
| Highest Target | 22.00 |
| Lowest Target | 22.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/300401.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300401.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300401.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.